Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth
Source: SeekingAlpha
2025-11-21 16:03:13 ET
In my article from October, "My Top 5 Biotech Stocks Big Pharma Could Buy Next," I mentioned how Phathom Pharmaceutical's ( PHAT ) Voquezna and Voquezna Triple Pak is actively capturing share in the U.S. GERD and H. pylori infection treatment markets. ...
Read the full article on Seeking Alpha
For further details see:
Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth
GlaxoSmithKline Plc
NASDAQ: GLAXF
GLAXF Trading
-1.49% G/L:
$27.04 Last:
200 Volume:
$27.04 Open:
GLAXF Latest News
GLAXF Stock Data
$123,941,620,346
2,019,018,428
0.4%
538
N/A
Pharmaceuticals
Healthcare
GB
London
